Compare Pfizer Inc (PFE) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Plby Group Inc — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Plby Group Inc trades at $1.28 (market cap $143.34M). The key difference: Pfizer Inc is far larger — about 991.6× Plby Group Inc's market cap, and Pfizer Inc pays a 6.9% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| PFE | PLBY | |
|---|---|---|
Market Cap | $142.14B | $143.34M |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $2.71 |
52-Week Low | $23.29 | $1.11 |
Enterprise Value | $192.80B | $291.14M |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
PLBY Group trades at $1.23, up 5.13% today, amid a bearish technical signal. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable. Recent developments include inclusion in the Russell 2000 and 3000 indices and a major share repurchase. Analyst consensus is strongly bullish with 75% buy ratings, reflecting optimism around the company's strategic focus on licensing, media, and experiences.
The outlook for PLBY hinges on sustaining its operational turnaround and achieving profitability. Key opportunities include brand monetization and cost management, while risks involve high debt levels and competitive pressures. Investors should weigh the strong analyst support against the company's historical losses and current negative equity position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
